Merger talks between Bristol Myers Squibb and AstraZeneca fade as Q2 earnings roll out and FDA advisory meetings heat up

Talks of a possible merger between Bristol Myers Squibb and AstraZeneca have receded after analysts highlighted antitrust hurdles. Both companies, each valued over $130 billion, were rumored to consider a deal that would have been the largest in pharma history. Analysts note that BMS faces looming patent expirations on its blood-thinner Eliquis and immunotherapy Opdivo, which together represent a significant share of its projected 2025 sales, and could stand to benefit more than AstraZeneca from a combination.

At the same time, the sector's second-quarter earnings season is underway. Pfizer disclosed an additional $2.5 billion in cost-saving initiatives slated through 2029, while Merck and other firms reported pipeline discontinuations and broader cost-cutting measures as they navigate patent cliffs and market pressures.

Regulatory attention is also intensifying. The FDA's advisory committees convened to discuss therapies from Capricor Therapeutics and Replimune, generating heated debate among panelists. The outcomes of these meetings could shape the approval pathways for the companies' experimental products.